The global market for Second-Generation Antipsychotics was valued at US$ 45000 million in the year 2024 and is projected to reach a revised size of US$ 50570 million by 2031, growing at a CAGR of 1.7% during the forecast period.
Second-generation antipsychotics, also known as atypical antipsychotics or novel antipsychotics. Compared with the first generation drugs, the second generation antipsychotic drugs have significant differences in pharmacological mechanisms, clinical efficacy, and side effect profiles, making them the mainstream choice for the treatment of severe mental disorders such as schizophrenia and bipolar disorder. From the perspective of pharmacological mechanisms, second-generation antipsychotics can be divided into four categories: 5-hydroxytryptamine and dopamine receptor antagonists (such as risperidone, olanzapine, quetiapine, and ziprasidone), multi receptor acting drugs (such as clozapine), selective dopamine receptor antagonists (such as amisulpride), and dopamine receptor partial agonists (such as aripiprazole).
The global market for second-generation antipsychotics has shown a growth trend in recent years. Core products such as olanzapine, quetiapine, and risperidone have long dominated sales, while relatively new drugs such as aripiprazole and ziprasidone have also shown good growth momentum. The main driving factors of the market include the increasing burden of mental illness, changes in treatment concepts, increased policy support, and breakthroughs in research and development innovation. The market has significant regional differences. Currently, North America holds the largest market share, with multinational pharmaceutical giants such as Pfizer, Eli Lilly, Novartis, and Merck dominating the market. The European market follows closely behind, with a slightly slower growth rate than North America, but the competitive landscape is more fragmented with numerous participants. In the Asia Pacific region, the Japanese market is relatively small and growing slowly, dominated by several large local pharmaceutical companies. The Chinese and Indian markets are not large in scale, but their growth rates are significantly higher than the global average, making them key regions for global pharmaceutical companies to layout. In the future, market differentiation will intensify, and original drugs with expired patents will face fierce competition from generic drugs, resulting in a significant decrease in prices, while new mechanism drugs with significant clinical advantages can gain premium space. Early intervention for mental illness will receive more attention, and the demand for low-dose formulations and drugs with fewer side effects suitable for early intervention will increase. Digital health technologies such as electronic prescriptions, telemedicine, and medication compliance monitoring will be deeply integrated with antipsychotic drug treatment. Emerging economies such as China and India will become important engines of global growth. With the improvement of medical infrastructure and increased payment capacity, the demand for high-quality antipsychotic drugs will rapidly grow, providing strategic opportunities for global pharmaceutical companies.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Second-Generation Antipsychotics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Second-Generation Antipsychotics.
The Second-Generation Antipsychotics market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Second-Generation Antipsychotics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Second-Generation Antipsychotics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sumitomo Dainippon Pharma
Roche
Pfizer
Novartis
Otsuka Pharmaceutical
AbbVie
Johnson And Johnson
Ipsen
Merck
Eli Lilly
Luye Pharma Group
Nhwa Pharmaceutical
Livzon Pharmaceutical Group
Qilu Pharmaceutical
CSPC Pharmaceutical Group
Chengdu Kanghong Pharmaceutical
Hansoh Pharma
Hisun Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Yangtze River Pharmaceutical Group
Segment by Type
5-Hydroxytryptamine And Dopamine Receptor Antagonists
Multi Receptor Acting Drugs
Selective Dopamine Receptor Antagonists
Dopamine Receptor Partial Agonists
Segment by Application
Schizophrenia
Bipolar Disorder
Adjuvant Treatment For Depression
Other Mental Illnesses
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Second-Generation Antipsychotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Second-Generation Antipsychotics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Second-Generation Antipsychotics Market Overview
1.1 Product Definition
1.2 Second-Generation Antipsychotics by Type
1.2.1 Global Second-Generation Antipsychotics Market Value Comparison by Type (2024 VS 2031)
1.2.2 5-Hydroxytryptamine And Dopamine Receptor Antagonists
1.2.3 Multi Receptor Acting Drugs
1.2.4 Selective Dopamine Receptor Antagonists
1.2.5 Dopamine Receptor Partial Agonists
1.3 Second-Generation Antipsychotics by Application
1.3.1 Global Second-Generation Antipsychotics Market Value by Application (2024 VS 2031)
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Adjuvant Treatment For Depression
1.3.5 Other Mental Illnesses
1.4 Global Second-Generation Antipsychotics Market Size Estimates and Forecasts
1.4.1 Global Second-Generation Antipsychotics Revenue 2020-2031
1.4.2 Global Second-Generation Antipsychotics Sales 2020-2031
1.4.3 Global Second-Generation Antipsychotics Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Second-Generation Antipsychotics Market Competition by Manufacturers
2.1 Global Second-Generation Antipsychotics Sales Market Share by Manufacturers (2020-2025)
2.2 Global Second-Generation Antipsychotics Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Second-Generation Antipsychotics Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Second-Generation Antipsychotics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Second-Generation Antipsychotics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Second-Generation Antipsychotics, Product Type & Application
2.7 Global Key Manufacturers of Second-Generation Antipsychotics, Date of Enter into This Industry
2.8 Global Second-Generation Antipsychotics Market Competitive Situation and Trends
2.8.1 Global Second-Generation Antipsychotics Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Second-Generation Antipsychotics Players Market Share by Revenue
2.8.3 Global Second-Generation Antipsychotics Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Second-Generation Antipsychotics Market Scenario by Region
3.1 Global Second-Generation Antipsychotics Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Second-Generation Antipsychotics Sales by Region: 2020-2031
3.2.1 Global Second-Generation Antipsychotics Sales by Region: 2020-2025
3.2.2 Global Second-Generation Antipsychotics Sales by Region: 2026-2031
3.3 Global Second-Generation Antipsychotics Revenue by Region: 2020-2031
3.3.1 Global Second-Generation Antipsychotics Revenue by Region: 2020-2025
3.3.2 Global Second-Generation Antipsychotics Revenue by Region: 2026-2031
3.4 North America Second-Generation Antipsychotics Market Facts & Figures by Country
3.4.1 North America Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Second-Generation Antipsychotics Sales by Country (2020-2031)
3.4.3 North America Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Second-Generation Antipsychotics Market Facts & Figures by Country
3.5.1 Europe Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Second-Generation Antipsychotics Sales by Country (2020-2031)
3.5.3 Europe Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Second-Generation Antipsychotics Market Facts & Figures by Region
3.6.1 Asia Pacific Second-Generation Antipsychotics Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Second-Generation Antipsychotics Sales by Region (2020-2031)
3.6.3 Asia Pacific Second-Generation Antipsychotics Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Second-Generation Antipsychotics Market Facts & Figures by Country
3.7.1 Latin America Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Second-Generation Antipsychotics Sales by Country (2020-2031)
3.7.3 Latin America Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Second-Generation Antipsychotics Market Facts & Figures by Country
3.8.1 Middle East and Africa Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Second-Generation Antipsychotics Sales by Country (2020-2031)
3.8.3 Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Second-Generation Antipsychotics Sales by Type (2020-2031)
4.1.1 Global Second-Generation Antipsychotics Sales by Type (2020-2025)
4.1.2 Global Second-Generation Antipsychotics Sales by Type (2026-2031)
4.1.3 Global Second-Generation Antipsychotics Sales Market Share by Type (2020-2031)
4.2 Global Second-Generation Antipsychotics Revenue by Type (2020-2031)
4.2.1 Global Second-Generation Antipsychotics Revenue by Type (2020-2025)
4.2.2 Global Second-Generation Antipsychotics Revenue by Type (2026-2031)
4.2.3 Global Second-Generation Antipsychotics Revenue Market Share by Type (2020-2031)
4.3 Global Second-Generation Antipsychotics Price by Type (2020-2031)
5 Segment by Application
5.1 Global Second-Generation Antipsychotics Sales by Application (2020-2031)
5.1.1 Global Second-Generation Antipsychotics Sales by Application (2020-2025)
5.1.2 Global Second-Generation Antipsychotics Sales by Application (2026-2031)
5.1.3 Global Second-Generation Antipsychotics Sales Market Share by Application (2020-2031)
5.2 Global Second-Generation Antipsychotics Revenue by Application (2020-2031)
5.2.1 Global Second-Generation Antipsychotics Revenue by Application (2020-2025)
5.2.2 Global Second-Generation Antipsychotics Revenue by Application (2026-2031)
5.2.3 Global Second-Generation Antipsychotics Revenue Market Share by Application (2020-2031)
5.3 Global Second-Generation Antipsychotics Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sumitomo Dainippon Pharma
6.1.1 Sumitomo Dainippon Pharma Company Information
6.1.2 Sumitomo Dainippon Pharma Description and Business Overview
6.1.3 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio
6.1.5 Sumitomo Dainippon Pharma Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Second-Generation Antipsychotics Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Second-Generation Antipsychotics Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Second-Generation Antipsychotics Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Otsuka Pharmaceutical
6.5.1 Otsuka Pharmaceutical Company Information
6.5.2 Otsuka Pharmaceutical Description and Business Overview
6.5.3 Otsuka Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.5.5 Otsuka Pharmaceutical Recent Developments/Updates
6.6 AbbVie
6.6.1 AbbVie Company Information
6.6.2 AbbVie Description and Business Overview
6.6.3 AbbVie Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AbbVie Second-Generation Antipsychotics Product Portfolio
6.6.5 AbbVie Recent Developments/Updates
6.7 Johnson And Johnson
6.7.1 Johnson And Johnson Company Information
6.7.2 Johnson And Johnson Description and Business Overview
6.7.3 Johnson And Johnson Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Johnson And Johnson Second-Generation Antipsychotics Product Portfolio
6.7.5 Johnson And Johnson Recent Developments/Updates
6.8 Ipsen
6.8.1 Ipsen Company Information
6.8.2 Ipsen Description and Business Overview
6.8.3 Ipsen Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Ipsen Second-Generation Antipsychotics Product Portfolio
6.8.5 Ipsen Recent Developments/Updates
6.9 Merck
6.9.1 Merck Company Information
6.9.2 Merck Description and Business Overview
6.9.3 Merck Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Merck Second-Generation Antipsychotics Product Portfolio
6.9.5 Merck Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly Second-Generation Antipsychotics Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 Luye Pharma Group
6.11.1 Luye Pharma Group Company Information
6.11.2 Luye Pharma Group Description and Business Overview
6.11.3 Luye Pharma Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Luye Pharma Group Second-Generation Antipsychotics Product Portfolio
6.11.5 Luye Pharma Group Recent Developments/Updates
6.12 Nhwa Pharmaceutical
6.12.1 Nhwa Pharmaceutical Company Information
6.12.2 Nhwa Pharmaceutical Description and Business Overview
6.12.3 Nhwa Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.12.5 Nhwa Pharmaceutical Recent Developments/Updates
6.13 Livzon Pharmaceutical Group
6.13.1 Livzon Pharmaceutical Group Company Information
6.13.2 Livzon Pharmaceutical Group Description and Business Overview
6.13.3 Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
6.13.5 Livzon Pharmaceutical Group Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Company Information
6.14.2 Qilu Pharmaceutical Description and Business Overview
6.14.3 Qilu Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
6.15 CSPC Pharmaceutical Group
6.15.1 CSPC Pharmaceutical Group Company Information
6.15.2 CSPC Pharmaceutical Group Description and Business Overview
6.15.3 CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.15.4 CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
6.15.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Company Information
6.16.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 Hansoh Pharma
6.17.1 Hansoh Pharma Company Information
6.17.2 Hansoh Pharma Description and Business Overview
6.17.3 Hansoh Pharma Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Hansoh Pharma Second-Generation Antipsychotics Product Portfolio
6.17.5 Hansoh Pharma Recent Developments/Updates
6.18 Hisun Pharmaceutical
6.18.1 Hisun Pharmaceutical Company Information
6.18.2 Hisun Pharmaceutical Description and Business Overview
6.18.3 Hisun Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.18.5 Hisun Pharmaceutical Recent Developments/Updates
6.19 Chia Tai Tianqing Pharmaceutical
6.19.1 Chia Tai Tianqing Pharmaceutical Company Information
6.19.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.19.3 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.20 Yangtze River Pharmaceutical Group
6.20.1 Yangtze River Pharmaceutical Group Company Information
6.20.2 Yangtze River Pharmaceutical Group Description and Business Overview
6.20.3 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
6.20.5 Yangtze River Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Second-Generation Antipsychotics Industry Chain Analysis
7.2 Second-Generation Antipsychotics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Second-Generation Antipsychotics Production Mode & Process Analysis
7.4 Second-Generation Antipsychotics Sales and Marketing
7.4.1 Second-Generation Antipsychotics Sales Channels
7.4.2 Second-Generation Antipsychotics Distributors
7.5 Second-Generation Antipsychotics Customer Analysis
8 Second-Generation Antipsychotics Market Dynamics
8.1 Second-Generation Antipsychotics Industry Trends
8.2 Second-Generation Antipsychotics Market Drivers
8.3 Second-Generation Antipsychotics Market Challenges
8.4 Second-Generation Antipsychotics Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Sumitomo Dainippon Pharma
Roche
Pfizer
Novartis
Otsuka Pharmaceutical
AbbVie
Johnson And Johnson
Ipsen
Merck
Eli Lilly
Luye Pharma Group
Nhwa Pharmaceutical
Livzon Pharmaceutical Group
Qilu Pharmaceutical
CSPC Pharmaceutical Group
Chengdu Kanghong Pharmaceutical
Hansoh Pharma
Hisun Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Yangtze River Pharmaceutical Group
听
听
*If Applicable.